Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 109
Filter
1.
Osteoarthritis Cartilage ; 29(11): 1600-1613, 2021 11.
Article in English | MEDLINE | ID: mdl-34419603

ABSTRACT

OBJECTIVE: The forkhead box O1 (FOXO1) transcription factor is a key regulator of autophagy. In chondrocytes, reduced FOXO1 expression with aging causes osteoarthritis due to dysfunction of autophagy, but the mechanisms underlying regulation of FOXO1 expression and the reduction in expression with aging remain unclear. We investigated the mechanism by which transforming growth factor ß1 (TGFß1) signaling regulates the FOXO1-autophagy axis. METHODS: Expression of FOXO1 was measured in chondrocytes after TGFß1 treatment. Immunohistochemistry was performed to estimate the levels of activin receptor-like kinase 5 (ALK5) and FOXO1 in the knee joints of young, middle-aged and old mice. The effects of the ALK5 inhibitor and SMAD3 or SMAD2 knockdown on FOXO1 expression were evaluated. The role of TGFß1 in autophagy after hydrogen peroxide (H2O2) treatment was analyzed. The protective effect of TGFß1 against H2O2 treatment was assessed by cell viability assay and TUNEL assay. RESULTS: TGFß1 promoted the expression of FOXO1 mRNA and protein. Both ALK5 and FOXO1 expression decreased with aging. ALK5 inhibition and SMAD3 knockdown suppressed induction of FOXO1 expression by TGFß1, whereas SMAD2 knockdown increased it. TGFß1 promoted the expression of microtubule-associated proteins 1A/1B light chain 3B (LC3)-I protein via the SMAD3-FOXO1 pathway. Furthermore, under H2O2 treatment, TGFß1 promoted expression of LC3-II. TGFß1 pretreatment suppressed cell death of chondrocytes following H2O2 treatment, but this protective effect was abolished by FOXO1 knockdown. CONCLUSIONS: TGFß1 protects chondrocytes against oxidative stress via the FOXO1-autophagy axis, and a reduction in ALK5 expression might cause reduced FOXO1 expression with aging.


Subject(s)
Chondrocytes/metabolism , Forkhead Box Protein O1/metabolism , Oxidative Stress/drug effects , Transforming Growth Factor beta1/pharmacology , Aging , Animals , Autophagy , Cell Death , Forkhead Box Protein O1/genetics , Humans , RNA, Messenger/metabolism , Receptor, Transforming Growth Factor-beta Type I/metabolism , Signal Transduction , Stifle/metabolism
2.
Cell Death Differ ; 21(12): 1971-83, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25124556

ABSTRACT

Mutation or multiplication of the alpha-synuclein (Syn)-encoding gene is frequent cause of early onset Parkinson's disease (PD). Recent evidences point to the pathogenic role of excess Syn also in sporadic PD. Syn is a cytosolic protein, which has been shown to be released from neurons. Here we provide evidence that extracellular Syn induces an increase in surface-exposed glucose-related protein of 78 kDa (GRP78), which becomes clustered in microdomains of the neuronal plasma membrane. Upon interacting with Syn, GRP78 activates a signaling cascade leading to cofilin 1 inactivation and stabilization of microfilaments, thus affecting morphology and dynamics of actin cytoskeleton in cultured neurons. Downregulation of GRP78 abolishes the activity of exogenous Syn, indicating that it is the primary target of Syn. Inactivation of cofilin 1 and stabilization of actin cytoskeleton are present also in fibroblasts derived from genetic PD patients, which show a dramatic increase in stress fibers. Similar changes are displayed by control cells incubated with the medium of PD fibroblasts, only when Syn is present. The accumulation of Syn in the extracellular milieu, its interaction with the plasma membrane and Syn-driven clustering of GRP78 appear, therefore, responsible for the dysregulation of actin turnover, leading to early deficits in synaptic function that precede neurodegeneration.


Subject(s)
Heat-Shock Proteins/metabolism , Neurons/metabolism , Signal Transduction , alpha-Synuclein/physiology , Actin Cytoskeleton/metabolism , Animals , Cells, Cultured , Cofilin 1/metabolism , Endoplasmic Reticulum Chaperone BiP , Hippocampus/cytology , Humans , Membrane Microdomains/metabolism , Mice, Inbred C57BL , Parkinson Disease/metabolism , Parkinson Disease/pathology , Protein Stability , Protein Transport
3.
Leukemia ; 28(7): 1459-66, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24457336

ABSTRACT

Myeloperoxidase (MPO) has been associated with both a myeloid lineage commitment and favorable prognosis in patients with acute myeloid leukemia (AML). DNA methyltransferase inhibitors (decitabine and zeburaline) induced MPO gene promoter demethylation and MPO gene transcription in AML cells with low MPO activity. Therefore, MPO gene transcription was directly and indirectly regulated by DNA methylation. A DNA methylation microarray subsequently revealed a distinct methylation pattern in 33 genes, including DNA methyltransferase 3 beta (DNMT3B), in CD34-positive cells obtained from AML patients with a high percentage of MPO-positive blasts. Based on the inverse relationship between the methylation status of DNMT3B and MPO, we found an inverse relationship between DNMT3B and MPO transcription levels in CD34-positive AML cells (P=0.0283). In addition, a distinct methylation pattern was observed in five genes related to myeloid differentiation or therapeutic sensitivity in CD34-positive cells from AML patients with a high percentage of MPO-positive blasts. Taken together, the results of the present study indicate that MPO may serve as an informative marker for identifying a distinct and crucial DNA methylation profile in CD34-positive AML cells.


Subject(s)
DNA (Cytosine-5-)-Methyltransferases/genetics , DNA Methylation , Gene Expression Regulation, Leukemic , Leukemia, Myeloid, Acute/genetics , Peroxidase/genetics , Antigens, CD34/metabolism , Bone Marrow/pathology , Bone Marrow Cells/metabolism , Bone Marrow Cells/pathology , CCAAT-Enhancer-Binding Proteins/genetics , Cell Line, Tumor , Cluster Analysis , DNA (Cytosine-5-)-Methyltransferases/metabolism , Epigenesis, Genetic , Gene Expression Profiling , Humans , Leukemia, Myeloid, Acute/metabolism , Leukemia, Myeloid, Acute/pathology , Mutation , Nuclear Proteins/genetics , Nucleophosmin , Peroxidase/metabolism , fms-Like Tyrosine Kinase 3/genetics , DNA Methyltransferase 3B
4.
J R Soc Interface ; 9(76): 3017-26, 2012 Nov 07.
Article in English | MEDLINE | ID: mdl-22696484

ABSTRACT

We demonstrate high-resolution photocross-linking of biodegradable poly(propylene fumarate) (PPF) and diethyl fumarate (DEF) using UV excimer laser photocuring at 308 nm. The curing depth can be tuned in a micrometre range by adjusting the total energy dose (total fluence). Young's moduli of the scaffolds are found to be a few gigapascal, high enough to support bone formation. The results presented here demonstrate that the proposed technique is an excellent tool for the fabrication of stiff and biocompatible structures on a micrometre scale with defined patterns of high resolution in all three spatial dimensions. Using UV laser photocuring at 308 nm will significantly improve the speed of rapid prototyping of biocompatible and biodegradable polymer scaffolds and enables its production in a few seconds, providing high lateral and horizontal resolution. This short timescale is indeed a tremendous asset that will enable a more efficient translation of technology to clinical applications. Preliminary cell tests proved that PPF : DEF scaffolds produced by excimer laser photocuring are biocompatible and, therefore, are promising candidates to be applied in tissue engineering and regenerative medicine.


Subject(s)
Biocompatible Materials/chemical synthesis , Cross-Linking Reagents/chemistry , Fumarates/chemistry , Photochemical Processes , Polypropylenes/chemistry , Biomechanical Phenomena , Cell Line, Tumor , Humans , Lasers , Materials Testing , Microscopy, Electron, Scanning , Polymerization , Spectrophotometry, Ultraviolet
5.
Leukemia ; 22(5): 956-64, 2008 May.
Article in English | MEDLINE | ID: mdl-18273043

ABSTRACT

Myeloperoxidase (MPO), a pivotal lineage marker for acute myeloid leukemia (AML), has been also shown to have a prognostic value: a high percentage of MPO-positive blasts correlates to favorable prognosis. To understand the relationship between the expression of MPO in leukemia cells and the response to chemotherapeutic agents, we established MPO-expressing K562 leukemia cell lines and then treated them with cytosine arabinocide (AraC). Cells expressing wild-type MPO, but not mutant MPO that could not mature, died earlier of apoptosis than control K562 cells. Reactive oxygen species (ROS) were generated more in leukemia cells expressing MPO, and the generation was abrogated by MPO inhibitors or antioxidants. Tyrosine nitration of cellular protein also increased more in MPO-expressing K562 cells than control cells after treatment with AraC. In clinical samples, CD34-positive AML cells from high-MPO cases showed a tendency to be sensitive to AraC in the colony-formation assay, and the generation of ROS and the nitration of protein were observed only when the percentage of MPO-expressing cells was high. These data suggest that MPO enhances the chemosensitivity of AML through the generation of ROS and the nitration of proteins.


Subject(s)
Antineoplastic Agents/pharmacology , Leukemia/pathology , Peroxidase/physiology , Protein Processing, Post-Translational , Reactive Oxygen Species/metabolism , Humans , K562 Cells , Leukemia/metabolism , Nitrosation , Peroxidase/analysis , Tumor Cells, Cultured
6.
Haematologica ; 93(1): e21-3, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18166773

ABSTRACT

Primary effusion lymphoma (PEL) was initially designated as a body-cavity-based lymphoma and recognized as a distinct clinical entity without a contiguous tumor mass. PEL was first reported in patients with acquired immunodeficiency syndrome (AIDS) and the distinctive feature of PEL originally reported as a B-cell neoplasm characterized by infection of the tumor cells by human herpes virus 8 (HHV-8). However, there have recently been several reports of PEL in patients without human immunodeficiency virus (HIV) or HHV-8 infection.


Subject(s)
CD4 Antigens/biosynthesis , DNA-Binding Proteins/genetics , Gene Rearrangement , Herpesvirus 8, Human/genetics , Lymphoma, Primary Effusion/genetics , Lymphopenia/therapy , T-Lymphocytes/metabolism , Aged , Antineoplastic Agents/pharmacology , Dyspnea/diagnosis , HIV Infections/diagnosis , Herpesvirus 8, Human/metabolism , Humans , Immunophenotyping , Lymphoma, Primary Effusion/complications , Lymphoma, Primary Effusion/therapy , Lymphopenia/complications , Male , Pericardial Effusion , Proto-Oncogene Proteins c-bcl-6
7.
Leukemia ; 21(6): 1212-7, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17410191

ABSTRACT

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can provide long-term remission for patients with adult T-cell leukemia/lymphoma (ATLL) caused by human retrovirus, human T-lymphocyte virus (HTLV-1). To understand how HTLV-1-positive cells including ATLL cells were suppressed by allo-HSCT, we examined HTLV-1 provirus load and residual ATLL cells in peripheral blood of transplant recipients using PCR-based tests. We found that the copy number of HTLV-1 genome, called provirus, became very small in number after allo-HSCT; however, in most cases, provirus did not disappear even among long-term survivors. Tumor-specific PCR tests demonstrated that most of HTLV-1-positive cells that remained long after transplantation were not primary ATLL cells but donor-derived HTLV-1-positive cells. We also found a case having very low amount of residual disease in peripheral blood even long after transplantation. There was only one recipient in whom we failed to show the presence of HTLV-1 genome and antibody against HTLV-1 even with an extensive search, which strongly suggested the elimination of HTLV-1 after allo-HSCT. These results demonstrated that after allo-HSCT the small amount of residual HTLV-1-positive cells were heterogeneous in origin and that long-term disease control for ATLL could be obtained without the complete elimination of HTLV-1.


Subject(s)
Hematopoietic Stem Cell Transplantation , Human T-lymphotropic virus 1/isolation & purification , Leukemia-Lymphoma, Adult T-Cell/therapy , Adult , Humans , Leukemia-Lymphoma, Adult T-Cell/pathology , Polymerase Chain Reaction , Remission Induction , Tissue Donors , Transplantation, Homologous , Viral Load
8.
Leukemia ; 21(4): 678-86, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17268513

ABSTRACT

In the criteria of refractory cytopenia with multilineage dysplasia (RCMD) according to the WHO (World Health Organization) classification, the frequency threshold concerning dysplasia of each lineage was defined as 10%. To predict overall survival (OS) and leukemia-free survival (LFS) for patients with refractory anemia (RA) according to the French-American-British (FAB) classification, we investigated prognostic factors based on the morphological features of 100 Japanese and 87 German FAB-RA patients, excluding 5q-syndrome. In the univariate analysis of all patients, pseudo-Pelger-Huet anomalies >or=10% (Pelger+), micromegakaryocytes >or=10% (mMgk+), dysgranulopoiesis (dys G) >or=10% and dysmegakaryopoiesis (dys Mgk) >or=40% were unfavorable prognostic factors for OS and LFS (OS; P<0.001, LFS; P<0.001). The prognostic effects of the morphological features were similar in both Japanese and German patients. However, dys Mgk >or=10% was not correlated with OS and LFS. In the multivariate analysis, mMgk+ and dys Mgk>or=40% were adverse prognostic factors for OS for all patients, and dys G >or=10% and dys Mgk>or=40% were adverse prognostic factors for LFS for all patients. On the basis of the present analysis, we propose the following modified morphological criteria for RCMD. Modified RCMD should be defined as FAB-RA, excluding 5q-syndrome with dys G >or=10%, dys Mgk>or=40% or mMgk+.


Subject(s)
Anemia/epidemiology , Megakaryocytes/pathology , Myelodysplastic Syndromes/classification , Myelodysplastic Syndromes/pathology , Adult , Chromosome Mapping , Female , Germany , Humans , Japan , Male , Middle Aged , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/mortality , Prognosis , Survival Analysis , Survivors , World Health Organization
9.
Pharmacol Biochem Behav ; 69(1-2): 17-22, 2001.
Article in English | MEDLINE | ID: mdl-11420064

ABSTRACT

Injections of lipopolysaccharide (LPS, 3 microg) into the lateral ventricle elicited anorexia with fever and also decreased body weight in rats. The LPS-induced anorexia was inhibited by intracerebroventicular (i.c.v.) injections of anti-interleukin (IL)-1beta antibody (Ab), chelerythrine, genistein and tyrphostin 46, but not by injections of indomethacin. Consecutive injections of orthovanadate and LPS (0.3 microg, a dose of LPS that did not show any effect on food intake, body weight or body temperature) reduced body weight, but did not induce anorexia. On the other hand, injections of IL-1beta (50 ng) did not influence food intake, although they decreased body weight and produced fever. The IL-1beta-induced decrease in body weight was inhibited by injections of genistein, but not by injections of chelerythrine or indomethacin. These findings suggest that the LPS-induced anorexia is independent of hyperthermia and involves IL-1beta generation, tyrosine kinase (TK) and protein kinase C (PKC). This is the first in vivo evidence that activation of TK and PKC induced by LPS is linked to anorexia.


Subject(s)
Anorexia/chemically induced , Anorexia/enzymology , Lipopolysaccharides/pharmacology , Protein Kinase C/metabolism , Protein-Tyrosine Kinases/metabolism , Animals , Body Weight/drug effects , Cyclooxygenase Inhibitors/pharmacology , Eating/drug effects , Enzyme Inhibitors/pharmacology , Indomethacin/pharmacology , Injections, Intraventricular , Interleukin-1/pharmacology , Male , Prostaglandins/pharmacology , Protein Kinase C/antagonists & inhibitors , Protein-Tyrosine Kinases/antagonists & inhibitors , Rats , Rats, Wistar , Signal Transduction/drug effects
10.
Clin Cancer Res ; 7(5): 1258-62, 2001 May.
Article in English | MEDLINE | ID: mdl-11350892

ABSTRACT

Plasma transforming growth factor beta1 (TGF-beta1) has been reported to be correlated with the extent of disease in colorectal cancer, but it is not known whether measuring this cytokine can help predict liver metastasis after curative resection. We prospectively studied whether plasma TGF-beta1 levels could predict liver metastasis in 117 patients with colorectal cancer before and after curative resection. Blood samples were drawn before and 2 weeks after surgery to determine the cytokine levels. Abdominal ultrasonography or computed tomography was done every 3 months after surgery. The primary end point for follow-up was recurrence. Seventy-seven of 117 cases (66%) had preoperative levels of the cytokine higher than the borderline limit of 7.5 ng/ml. Postoperative levels were >7.5 ng/ml in 29 of 117 patients (25%). The median follow-up period was 42 months (range, 5--66 months), with follow-up of all 117 patients. No recurrence was observed in 13 patients with Dukes' stage A lesions. Liver metastasis occurred in 18 of 104 patients (17%) with Dukes' stage B or C disease. Fourteen of 18 patients (78%) who developed liver metastasis had shown a postoperative plasma TGF-beta1 level of >7.5 ng/ml. Cox proportional hazards regression analysis showed that the postoperative level was a significant predictive factor for liver metastasis (P < 0.001). A single point measurement of plasma TGF-beta1 levels at 2 weeks after curative resection seems to be able to predict liver metastasis in colorectal cancer. This finding suggests the value of a prospective trial of liver-targeted adjuvant therapy for patients with elevated postoperative plasma TGF-beta1 levels.


Subject(s)
Biomarkers, Tumor/blood , Colorectal Neoplasms/pathology , Liver Neoplasms/diagnosis , Transforming Growth Factor beta/blood , Aged , Colorectal Neoplasms/blood , Colorectal Neoplasms/mortality , Disease Progression , Disease-Free Survival , Female , Humans , Liver Neoplasms/mortality , Liver Neoplasms/secondary , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Postoperative Care , Preoperative Care , Prognosis , Recurrence , Transforming Growth Factor beta1
11.
J Immunol ; 165(7): 3907-16, 2000 Oct 01.
Article in English | MEDLINE | ID: mdl-11034398

ABSTRACT

The present study investigates the regulatory mechanisms involved in the cooperation between IFN-gamma and TNF-alpha to promote transcription from IFN regulatory factor-1 (IRF-1). A transient transfection analysis revealed that the region between -218 and -144, where +1 is the transcription start site, as well as previously reported downstream elements, ppkappaB and IFN-gamma activation site/kappaB, were required for the optimal response to the two cytokines. A subsequent DNase I footprint analysis showed that the region between -171 and -144 was inducibly protected with stimulation by TNF-alpha, and this protection was significantly enhanced with the combination of IFN-gamma and TNF-alpha. In an EMSA with the protected region as a probe, a TNF-alpha-inducible complex (C1) and an IFN-gamma-inducible complex (C2), but no synergy-specific DNA-protein complexes, were recognized. The C1 complex consisted of a pre-existing factor (p65/p50), whereas the C2 complex consisted of a newly synthesized IRF-1-related factor. A methylation interference assay revealed the critical G residues (from -167 to -151) for the DNA-protein complex formation specific to the cytokine response, and within this region the novel kappaB sequence, the promoter distal kappaB (pdkappaB) element (5'-GGGGAAG TAC-3'), was identified. Because the base substitutions over the pdkappaB region (from -171 to -144) affected not only the TNF-alpha-response but also that of IFN-gamma, this region might contribute to the cooperative action of the NF-kappaB subunits with the IRF-1-related factor. Finally, we demonstrated that none of the cis-acting elements, ppkappaB, pdkappaB, or IFN-gamma activation site/kappaB, is dispensable for the optimal synergism in response to IFN-gamma and TNF-alpha.


Subject(s)
Cytokines/physiology , DNA-Binding Proteins/genetics , Phosphoproteins/genetics , Promoter Regions, Genetic/immunology , Response Elements/immunology , Adjuvants, Immunologic/physiology , Binding Sites/genetics , Binding Sites/immunology , Cells, Cultured , DNA-Binding Proteins/analysis , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/isolation & purification , DNA-Binding Proteins/metabolism , Gene Expression Regulation/immunology , Humans , Interferon Regulatory Factor-1 , Interferon-gamma/metabolism , Interferon-gamma/physiology , K562 Cells , NF-kappa B/biosynthesis , NF-kappa B/isolation & purification , NF-kappa B/metabolism , NF-kappa B p50 Subunit , Phosphoproteins/analysis , Transcription Factor RelA , Transcription Factors/biosynthesis , Transcription Factors/metabolism , Transcription, Genetic/immunology , Tumor Necrosis Factor-alpha/physiology , U937 Cells
12.
Can J Physiol Pharmacol ; 78(9): 729-36, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11007536

ABSTRACT

To elucidate the possible role of Rho A/Rho-kinase on lysophosphatidic acid (LPA)-induced contraction in intact guinea-pig ileal smooth muscle, we examined effects of pretreatment with a specific inhibitor of Rho-kinase (Y-27632) on the LPA-induced contraction and MLC20 phosphorylation. In addition, we investigated whether LPA actually elicits an activation of Rho A by studying subcellular distribution of Rho A in unstimulated and stimulated smooth muscles by LPA. LPA induced a less intense, but sustained, contraction compared with ACh, and was accompanied by significant increases in MLC20 phosphorylation. The effects of LPA on tension and MLC20 phosphorylation were inhibited by Y-27632. The ACh-induced contraction, but not increases in MLC20 phosphorylation, was partially inhibited by Y-27632. High K+-induced contraction was unaffected by the inhibitor. LPA stimulated translocation of Rho A from the cytosol to the membrane fraction of the muscle. Translocation of Rho A was also induced by ACh and high K+. These results suggest that LPA-induced contraction of intact ileal smooth muscle is dominated through activation of Rho A and Rho-kinase and subsequent increases in MLC20 phosphorylation.


Subject(s)
Ileum/drug effects , Lysophospholipids/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , rhoA GTP-Binding Protein/drug effects , Acetylcholine/pharmacology , Amides/pharmacology , Animals , Guinea Pigs , Ileum/physiology , Intracellular Signaling Peptides and Proteins , Male , Muscle Contraction/physiology , Muscle Relaxants, Central/pharmacology , Muscle, Smooth/physiology , Phosphorylation , Protein Serine-Threonine Kinases/drug effects , Protein Serine-Threonine Kinases/metabolism , Pyridines/pharmacology , Signal Transduction/drug effects , Signal Transduction/physiology , Vasodilator Agents/pharmacology , rho-Associated Kinases , rhoA GTP-Binding Protein/metabolism
13.
Brain Res ; 852(2): 367-73, 2000 Jan 10.
Article in English | MEDLINE | ID: mdl-10678764

ABSTRACT

We measured the rectal temperature of free-moving, conscious rats after intracerebroventricular (i.c.v.) injections of lipopolysaccharide (LPS) and interleukin-1beta (IL-1beta) with or without various antagonists to investigate the mechanisms involved in LPS-induced fever. LPS (3 microg) elicited significant increases in rectal temperature, which lasted from 0.5 h to more than 8 h after administration. This febrile response was inhibited by pretreatment with L-nitro-arginine (LNA), indomethacin (IND), genistein (GEN), tyrphostin 46 and anti-rat IL-1beta antibody (anti-IL-1beta Ab), but was not inhibited by pretreatment with daidzein or chelerythrine (CHE) into the ventricle. LPS (0.3 microg) following orthovanadate (i.c.v.) produced fever, although the small amount of LPS (0.3 microg) or orthovanadate alone showed no effect on rectal temperature. I.c.v. injections of IL-1beta also induced fever of approximately 4-h duration. This effect was inhibited by pretreatment with IND and anti-IL-1beta Ab, but was not inhibited by pretreatment with LNA, GEN or CHE into the ventricle. These findings demonstrate that in the central nervous system, LPS increases IL-1beta production after activation of tyrosine kinase and NO synthase, and IL-1beta promotes prostaglandin production resulting in increased rectal temperature. Activation of tyrosine kinase in the central nervous system is probably a trigger for the febrile response induced by LPS.


Subject(s)
Brain/enzymology , Fever/metabolism , Lipopolysaccharides , Protein-Tyrosine Kinases/metabolism , Animals , Antibodies/pharmacology , Body Temperature/drug effects , Brain/drug effects , Enzyme Inhibitors/pharmacology , Fever/chemically induced , Genistein/pharmacology , Injections, Intraventricular , Interleukin-1/biosynthesis , Interleukin-1/immunology , Male , Protein-Tyrosine Kinases/antagonists & inhibitors , Rats , Rats, Wistar , Rectum , Sphingosine/analogs & derivatives , Sphingosine/pharmacology , Tumor Necrosis Factor-alpha/pharmacology
14.
Biochem Biophys Res Commun ; 259(3): 683-7, 1999 Jun 16.
Article in English | MEDLINE | ID: mdl-10364479

ABSTRACT

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) has been reported to stimulate DNA synthesis of the hepatocytes in culture and highly express in regenerating rat liver after partial hepatectomy. We examined mitogenic effects and activation of transcription factors caused by exogenous human HB-EGF (hHB-EGF) in mouse liver. The mean labeling index in hepatocytes of hHB-EGF-injected mice was 2.6%, a significant increase over that in saline-injected controls (under 0.01%). By exogenous hHB-EGF injection, activation of transcription factors such as nuclear factor (NF)-kappaB and activator factor (AP)-1 was observed in the liver. By Northern blot analysis, hepatocyte growth factor (HGF) gene expression in the liver was found to be induced in the hHB-EGF-injected mice. In conclusion, intravenously injected hHB-EGF showed a limited but definite effect on the DNA synthesis of hepatocytes in the mice liver. HB-EGF may serve as a hepatotrophic factor in vivo.


Subject(s)
DNA/biosynthesis , Epidermal Growth Factor/pharmacology , Liver/metabolism , Animals , Cells, Cultured , Heparin-binding EGF-like Growth Factor , Hepatocyte Growth Factor/metabolism , Humans , Intercellular Signaling Peptides and Proteins , Liver/drug effects , Male , Mice , Mice, Inbred BALB C , Time Factors
15.
Jpn J Pharmacol ; 79(2): 237-41, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10202860

ABSTRACT

Intracerebroventricular injections of capsaicin at 100-500 nmol elicited dose-dependent decreases in urine outflow volume in anesthetized, hydrated rats. The capsaicin (500 nmol)-induced antidiuresis was inhibited by pretreatment with CP96345 (30 nmol, a neurokinin-1-receptor antagonist), but not by that with phenoxybenzamine (20 nmol, an alpha-adrenoceptor antagonist), timolol (100 nmol, a beta-adrenoceptor antagonist) or atropine (300 nmol, a muscarinic antagonist) into the hypothalamic supraoptic nucleus (SON). Intravenous injections of d(CH2)5-D-Tyr(Et)VAVP (50 microg/kg, a vasopressin-receptor antagonist) completely blocked the antidiuresis. In intra-SON microdialysis experiments, acetylcholine concentration in the perfusate of the capsaicin-injected rats was not different from that of the vehicle-injected rats. These findings suggested that capsaicin stimulated substance P release in the SON and caused the antidiuresis as a result of the increased release of vasopressin into the circulation from the neurohypophysis mediated through neurokinin-1 receptors in the SON.


Subject(s)
Capsaicin/pharmacology , Diuresis/drug effects , Receptors, Neurokinin-1/drug effects , Substance P/metabolism , Vasopressins/metabolism , Acetylcholine/metabolism , Anesthesia , Animals , Atropine/pharmacology , Binding Sites , Biphenyl Compounds/pharmacology , Dose-Response Relationship, Drug , Hypnotics and Sedatives/pharmacology , Injections, Intraventricular , Male , Microdialysis , Phenoxybenzamine/pharmacology , Rats , Rats, Wistar , Receptors, Neurokinin-1/physiology , Supraoptic Nucleus , Time Factors , Timolol/pharmacology
16.
Exp Hematol ; 27(3): 433-40, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10089905

ABSTRACT

We investigated the expression of Fas antigen (CD95) in the pure erythroid cell line AS-E2 in the presence and absence of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha). TNF-alpha induced apoptosis in AS-E2 cells, whereas IFN-gamma did not. In culture containing no IFN-gamma or TNF-alpha, AS-E2 cells expressed little Fas antigen. However, IFN-gamma and IFN-gamma and TNF-alpha both induced expression of Fas antigen and its mRNA within 24 hours after the stimulation. When anti-Fas monoclonal antibody (IgM) was added to AS-E2 cells after the induction of Fas expression, AS-E2 cells underwent apoptosis as shown by the induction of DNA fragmentation. This apoptotic change was inhibited by an inhibitor of caspase-3-like proteases (Ac-DEVD-CHO) and an inhibitor of CED-3/ICE family proteases (Z-Asp-CH2-DCB) but not by an inhibitor of caspase-1-like proteases (Ac-YVAD-CHO), suggesting a role for caspase-3-like proteases in Fas-receptor signaling. Although AS-E2 cells expressed Fas ligand mRNA, treatment with ZB4, an antibody that inhibits Fas-mediated cell death, failed to suppress IFN-gamma- or TNF-alpha-mediated cytotoxicity. These findings suggest that the late erythroid progenitor cells are negatively regulated by IFN-gamma and TNF-alpha, both of which are capable of inducing functional Fas expression.


Subject(s)
Apoptosis/drug effects , Erythroid Precursor Cells/drug effects , Gene Expression Regulation/drug effects , Interferon-gamma/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , fas Receptor/biosynthesis , Antibodies, Monoclonal/pharmacology , Apoptosis/physiology , Aspartic Acid/analogs & derivatives , Aspartic Acid/pharmacology , Caspase 3 , Caspase Inhibitors , Caspases/biosynthesis , Caspases/physiology , Cell Division/drug effects , DNA Fragmentation , Enzyme Inhibitors/pharmacology , Erythroid Precursor Cells/cytology , Erythroid Precursor Cells/metabolism , Fas Ligand Protein , Humans , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/genetics , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Oligopeptides/pharmacology , RNA, Messenger/biosynthesis , RNA, Neoplasm/biosynthesis , Recombinant Proteins , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects , Tumor Cells, Cultured , fas Receptor/genetics , fas Receptor/physiology
18.
J Hepatol ; 30(1): 1-7, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9927144

ABSTRACT

BACKGROUND/AIM: Transforming growth factor-beta1 is involved in liver fibrosis. Our aim was to examine the association of plasma transforming growth factor-beta1 levels with the degree of liver fibrosis. METHODS: We analyzed plasma transforming growth factor-beta1 levels in 43 patients with chronic hepatitis C treated with interferon-alpha using a transforming growth factor-beta1 ELISA. The content of transforming growth factor-beta1 in liver tissue obtained by needle biopsy (n=13) was also analyzed. The degree of liver fibrosis was assessed histologically and morphometrically. RESULTS: Plasma transforming growth factor-beta1 levels were significantly correlated with transforming growth factor-beta1 content in liver tissue (r=0.83, p<0.001), indicating that plasma levels correspond with tissue cytokine. Plasma transforming growth factor-beta1 levels in patients (8.1+/-1.1 ng/ml) before interferon-a therapy were significantly higher than in controls (1.9+/-0.3 ng/ml) (p<0.01). Plasma levels were significantly correlated with the degree of fibrosis (p<0.01). Plasma transforming growth factor-beta1 levels were significantly decreased in sustained responders (from 5.2+/-1.0 ng/ml to 2.9+/-0.7 ng/ml), relapsed patients (from 9.8+/-2.0 ng/ml to 3.4+/-0.6 ng/ml), and nonresponders (from 9.3+/-2.1 ng/ml to 3.9+/-0.9 ng/ml) at the end of therapy (p<0.05 for all comparisons). Significant regression of liver fibrosis after therapy was observed in both sustained responders and nonresponders (p<0.05 for both). CONCLUSIONS: These observations suggest that plasma transforming growth factor-beta1 levels appear to be associated with the degree of liver fibrosis.


Subject(s)
Hepatitis C, Chronic/blood , Hepatitis C, Chronic/therapy , Interferon-alpha/therapeutic use , Transforming Growth Factor beta/blood , Aged , Biopsy, Needle , Enzyme-Linked Immunosorbent Assay , Female , Hepatitis C, Chronic/complications , Humans , Liver/pathology , Liver Cirrhosis/pathology , Liver Cirrhosis/virology , Male , Middle Aged
19.
Leukemia ; 13(2): 215-21, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10025895

ABSTRACT

We established a simple IL-2-dependent colony-forming assay for T cells infected with human T-lymphotropic virus type-I (HTLV-I). IL-2-dependent cell lines were subsequently established by expanding individual colonies in liquid cultures. Lymphocyte-rich fractions were prepared from 31 HTLV-I carriers, 12 patients with smoldering ATL, 11 chronic ATL, 12 crisis ATL and 10 acute ATL. Primary colonies of CD4+ p19+ T cells were formed in all cases of carriers, smoldering and chronic ATL, and in 10 of 12 crisis cases. In contrast, no colony was formed from cells of patients with acute ATL. The rate of establishment of cell lines in HTLV-I carriers was significantly lower than that in patients of prodromal phase ATL. Cell lines established from cells of three prodromal cases were clonally identical to the parent ATL cells, while others had clonally distinct cell lines. Our results indicated the presence of four components of HTLV-I-infected T cells: (1) normal carrier T cells capable of forming colonies but not cell lines; (2) pre-malignant T cells capable of forming colonies as well as cell lines; (3) malignant T cells capable of forming colonies as well as cell lines; (4) fully malignant T cells unresponsive to IL-2. Our results suggest the presence of a multiclonal expansion of unique T cells in the prodromal phase of ATL, which have a high growth potential in response to IL-2. The coexistence of multiclonality with a dominant ATL clone may be closely related to the underlying pathology in HTLV-I leukemogenesis.


Subject(s)
HTLV-I Infections/drug therapy , Interleukin-2/therapeutic use , Leukemia-Lymphoma, Adult T-Cell/virology , Case-Control Studies , Cell Division/drug effects , Clone Cells , Colony-Forming Units Assay , Disease Progression , Female , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor , HTLV-I Infections/immunology , Humans , Immunophenotyping , Leukemia-Lymphoma, Adult T-Cell/immunology , Male , Middle Aged , Viral Proteins/biosynthesis
20.
J Gastroenterol Hepatol ; 14(12): 1203-9, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10634158

ABSTRACT

BACKGROUND: Heparin-binding epidermal growth factor-like growth factor is an hepatotrophic factor expressed in non-parenchymal liver cells but not in hepatocytes in regenerating rat liver after partial hepatectomy. Human hepatocellular carcinoma cells also produce this growth factor. In this study, the expression of the growth factor in the hepatocytes of fibrotic liver during hepatocarcinogenesis was investigated. METHODS: Hepatic fibrosis was induced in rats by oral administration of 0.05% thioacetamide. Hepatocytes were isolated by in situ perfusion methods. Growth factor gene and protein expression were investigated by northern hybridization and immunohistochemistry, respectively. Expression of glutathione s-transferase P, which is expressed when hepatocytes undergo neoplastic transformation, was also investigated. RESULTS: Some hepatocytes in fibrotic liver, but not in normal liver, stained positively by immunohistochemistry for heparin-binding epidermal growth factor-like growth factor. The growth factor and glutathione s-transferase P gene transcript were present in hepatocytes isolated from fibrotic liver, but not in those isolated from normal liver. Immunohistochemical localization of both proteins in fibrotic liver revealed similar patterns. CONCLUSIONS: In essence, hepatocytes in fibrotic rat liver produce heparin-binding epidermal growth factor-like growth factor. Expression of this growth factor may occur as hepatocytes are transformed to a neoplastic phenotype.


Subject(s)
Epidermal Growth Factor/metabolism , Liver Cirrhosis, Experimental/metabolism , Animals , Carcinoma, Hepatocellular/metabolism , Electrophoresis, Agar Gel , Glutathione Transferase/metabolism , Heparin-binding EGF-like Growth Factor , Immunohistochemistry , Intercellular Signaling Peptides and Proteins , Liver/cytology , Liver Cirrhosis, Experimental/chemically induced , Liver Cirrhosis, Experimental/pathology , Liver Neoplasms/metabolism , Male , Rats , Rats, Sprague-Dawley , Thioacetamide
SELECTION OF CITATIONS
SEARCH DETAIL
...